Cite
HARVARD Citation
Herrera, A. et al. (n.d.). Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma. American journal of hematology. 95 (1), pp. 18-27. [Online].